ArticleMolecular biology reports2026
Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveMicroglial polarization toward the M1 phenotype is a key contributor to the initiation and progression of neuroinflammatory diseases, primarily through the release of pro-inflammatory cytokines that exacerbate central nervous system-associated injury. Activation of N-methyl-D-aspartic acid receptors (NMDARs) is implicated in microglial overactivation and cytotoxicity. This study aimed to investigate the role of esketamine, a non-competitive NMDAR antagonist, on microglial polarization.
methodsBV2 microglial cells were used as an in vitro model. Inhibitors and agonists were applied to modulate the mammalian target of rapamycin (mTOR) and brain-derived neurotrophic factor (BDNF)-tyrosine kinase receptor B (TrkB) signaling pathways. Small interfering RNA, Western blotting, enzyme-linked immunosorbent assay, and immunofluorescence staining were performed to investigate the regulatory effects and molecular targets of esketamine on BV2 cells.
resultsEsketamine enhanced mTOR phosphorylation and activated the BDNF-TrkB signaling pathway through NMDAR inhibition. This effect attenuated lipopolysaccharide-induced M1 polarization in BV2 microglia and reduced pro-inflammatory cytokine expression. Further analysis revealed that the anti-inflammatory effects of esketamine were primarily mediated by the NMDAR2A subtype, while the NMDAR2B subtype was not involved.
conclusionEsketamine suppressed proinflammatory microglial polarization by selectively modulating the NMDAR2A subtype, leading to the activation of the mTOR signaling pathway and enhancement of the BDNF-TrkB signaling pathway.
Indexed as
Identifiers
42911293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.